GITNUX MARKETDATA REPORT 2024

Nuvaring Effectiveness Onset Period Statistics

Nuvaring typically becomes effective as a contraceptive within 7 days of insertion, with the highest effectiveness achieved when used consistently and correctly over time.

Statistic 1

"NuvaRing is over 91% effective at preventing pregnancy when used correctly."

Sources Icon

Statistic 2

"The onset of action for NuvaRing occurs within 2-3 hours of insertion."

Sources Icon

Statistic 3

"After removal of the NuvaRing, the return to fertility (ovulation) can be as soon as 14 days."

Sources Icon

Statistic 4

"The NuvaRing has a typical use effectiveness rate of around 87%."

Sources Icon

Statistic 5

"If the NuvaRing is not inserted at the right time in the menstrual cycle, the effectiveness could drop to as low as 84%."

Sources Icon

Statistic 6

"NuvaRing can be used immediately after a miscarriage or abortion and the effectiveness would be approximately 99%/ effective if perfectly used."

Sources Icon

Statistic 7

"Breakthrough bleeding or spotting occurs in approximately 19% of women using the NuvaRing."

Sources Icon

Statistic 8

"Less than 1% of the time, users may experience device expulsion with NuvaRing."

Sources Icon

Statistic 9

"2.1% of NuvaRing users may stop using the ring due to vaginal symptoms."

Sources Icon

Statistic 10

"The percentage of cycles with perfect compliance was 88% for NuvaRing users."

Sources Icon

Statistic 11

"Approximately 0.1% of NuvaRing users experience a serious adverse event."

Sources Icon

Statistic 12

"In clinical trials, nearly 94% percent of rings stayed in place for the entire 3-week period."

Sources Icon

Statistic 13

"The risk of non-fatal venous thromboembolism is higher in Nuvaring users than in non-users, with a reported risk ratio of 1.9."

Sources Icon

Statistic 14

"Among every 100 women using Nuvaring for one year, about 9 may get pregnant."

Sources Icon

Statistic 15

"Over half of NuvaRing users report decreased flow length and period pain."

Sources Icon

Statistic 16

"NuvaRing use was associated with a 6.5-fold increased risk of confirmed venous thromboembolism."

Sources Icon

Statistic 17

"The rate of discontinuation because of an adverse event was 1.3 with NuvaRing."

Sources Icon

... Before You Leave, Catch This! 🔥

Your next business insight is just a subscription away. Our newsletter The Week in Data delivers the freshest statistics and trends directly to you. Stay informed, stay ahead—subscribe now.

Sign up for our newsletter and become the navigator of tomorrow's trends. Equip your strategy with unparalleled insights!